CHEK Projected Dividend Yield

Check-Cap Ltd ( NASDAQ : CHEK )

Check-Cap is a clinical stage medical diagnostics company. Co. has introduced the C-Scan® test designed to detect polyps before they transform into cancer. The disruptive capsule-based screening technology utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. Co.'s C-Scan system is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient's back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

20 YEAR PERFORMANCE RESULTS